{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:30:22Z","timestamp":1759581022033},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,4,14]],"date-time":"2004-04-14T00:00:00Z","timestamp":1081900800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Immunogenetics"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A bank of Epstein\u2010Barr virus (EBV)\u2010transformed B\u2010lymphoblastoid cell lines (BCLs) has been established in this laboratory over the last 7\u00a0years. Novel, rare and unusual HLA phenotypes were highlighted during routine clinical testing and during typing of volunteer haematopoietic stem cell donors for the Welsh Bone Marrow Donor Registry. The BCLs are routinely used as laboratory reagents, as a source of DNA for reference purposes and for research work. Consenting donors are tested for hepatitis B surface antigens (HBsAg), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) before their B\u2010lymphocytes are transformed. Strict bio\u2010identity checks are performed before and after transformation and after each BCL expansion. Each BCL is tested regularly for mycoplasma contamination. A total of 230 blood samples were transformed. One hundred and fifty\u2010nine sterile samples produced 157 BCLs (98.7% success), while 71 non\u2010sterile samples produced 50 BCLs (70.4% success), giving an overall success rate of 90.0%. Fifteen of the transformation failures have since been repeated successfully. Factors contributing to the high success rate and reasons for the 23 failed transformations are discussed. The successful development and use of pools of BCLs for HLA antibody screening by flow cytometry are described. Whilst certain training and health and safety issues require close attention, it is clear that EBV transformation of B lymphocytes and\/or the use of BCLs is feasible in a routine tissue typing laboratory and that BCLs are a valuable resource. Careful adherence to the methods and procedures detailed here should virtually guarantee successful transformation (98.7%) from good quality, sterile whole blood samples.<\/jats:p>","DOI":"10.1111\/j.1365-2370.2004.00450.x","type":"journal-article","created":{"date-parts":[[2004,4,14]],"date-time":"2004-04-14T13:40:51Z","timestamp":1081950051000},"page":"87-92","source":"Crossref","is-referenced-by-count":18,"title":["Provision of Epstein\u2010Barr virus\u2010transformed B\u2010cell lines in a routine tissue typing laboratory: practicalities and applications"],"prefix":"10.1111","volume":"31","author":[{"given":"H.","family":"Bass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Darke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,4,14]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Second Supplement (2000) to: Categorisation of Biological Agents According to Hazard and Categories of Containment","author":"Advisory Committee on Dangerous Pathogens","year":"2000"},{"key":"e_1_2_6_3_1","volume-title":"Cell and Tissue Culture: Laboratory Procedures","author":"Bolton B.","year":"1996"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702217"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000019057"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2000.560514.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2003.00113.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1089\/gte.2004.8.301"},{"key":"e_1_2_6_9_1","volume-title":"A Conspiracy of Cells.","author":"Gold M.","year":"1986"},{"key":"e_1_2_6_10_1","first-page":"513","article-title":"Rapid antibody screening using EBV cell pools","volume":"20","author":"Heads A.J.","year":"1993","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_11_1","volume-title":"Cell and Tissue Culture: Laboratory Procedures","author":"Morris C.","year":"1996"},{"key":"e_1_2_6_12_1","volume-title":"Cell and Tissue Culture: Laboratory Procedures","author":"Mowles J.","year":"1996"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2370.2003.00372.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2003.00033.x"},{"key":"e_1_2_6_15_1","volume-title":"Guidelines for the Use of Cell Lines in Cancer Research","author":"United Kingdom Co\u2010ordinating Committee on Cancer Research","year":"1999"},{"key":"e_1_2_6_16_1","first-page":"493","article-title":"ELISA screening and identification kit findings on cytotoxic negative renal sera","volume":"28","author":"Walters R.","year":"2001","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_17_1","first-page":"363","article-title":"ELISA testing on cytotoxicity negative but flow cytometry positive renal patients\u2019 sera","volume":"29","author":"Walters R.","year":"2002","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_18_1","first-page":"58","article-title":"Comprehensive renal patient antibody screening by cytotoxicity, flow cytometry and ELISA","volume":"26","author":"Walters R.","year":"1999","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_19_1","first-page":"290","article-title":"Comparison between cytotoxicity, flow cytometry and two ELISA kits for renal patient HLA\u2010class I and II antibody screening","volume":"27","author":"Walters R.","year":"2000","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_20_1","first-page":"320","article-title":"A study of CDC negative, flow cytometry and ELISA screen positive renal patients\u2019 sera","volume":"30","author":"Walters R.","year":"2003","journal-title":"European Journal of Immunogenetics"},{"key":"e_1_2_6_21_1","first-page":"11","volume-title":"Immunobiology of HLA","author":"Yang S.Y.","year":"1987"}],"container-title":["European Journal of Immunogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2370.2004.00450.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2370.2004.00450.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T06:28:38Z","timestamp":1697178518000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2370.2004.00450.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1111\/j.1365-2370.2004.00450.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2370.2004.00450.x","archive":["Portico"],"relation":{},"ISSN":["0960-7420","1365-2370"],"issn-type":[{"value":"0960-7420","type":"print"},{"value":"1365-2370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}